SNX16 and breast cancer: However, SNX16 was also reported to stimulate EGF receptor degradation in COS‐7 cells (Choi et al., 2004) and a previous study has shown that SNX16 overexpression in MCF‐7 breast cancer cell lines could decrease migration and tumor size in a mouse xenograft model (Zhang et al., 2013).